UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 15, 1998
ACCESS PHARMACEUTICALS, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE
----------------------------------------------
(State of other jurisdiction of incorporation)
0-9314 83-0221517
- ------------------------ ---------------------------------
(Commission File Number) (IRS Employer Identification No.)
2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207
----------------------------------------------- --------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:
----------------------------------------------------
(214) 905-5100
N/A
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
Item 4. Changes in Registrant's Certifying Accountants
Effective December 15, 1998, Access Pharmaceuticals, Inc. engaged Grant Thornton
LLP as its principal accountants. During the last two fiscal years and the
subsequent interim period to the date hereof, the Company did not consult
Grant Thornton LLP regarding any of the matters or events set forth in Item
304 (a) (2) (i) and (ii) of Regulation S-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company
has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
ACCESS PHARMACEUTICALS, INC.
By: /s/ Kerry P. Gray
--------------------
Title: President and CEO
Dated: December 18, 1998
